DALLAS / Feb 06, 2025 / Business Wire / Sonida Senior Living, Inc. (“Sonida” or the “Company”) (NYSE: SNDA), a leading owner, operator and investor in senior living communities, announced today that Brandon Ribar, President & Chief Executive Officer, Kevin Detz, Chief Financial Officer and Max Levy, Chief Investment Officer, will participate in Morgan Stanley’s Annual Commercial Real Estate Conference on Wednesday, February 19th and Thursday, February 20th at the Morgan Stanley Headquarters in New York City.
Management will be available for one-on-one meetings with institutional investors during the conference. To schedule a meeting, please contact your bank representative.
In addition, Mr. Ribar is scheduled to participate in a moderated panel discussion entitled “Longevity and Senior Living,” on Wednesday, February 19th from 10:15 a.m. – 10:55 a.m. EST.
About Sonida
Dallas-based Sonida Senior Living, Inc. is a leading owner, operator and investor in independent living, assisted living and memory care communities and services for senior adults. The Company provides compassionate, resident-centric services and care as well as engaging programming operating 94 senior housing communities in 20 states with an aggregate capacity of over 10,000 residents, including 81 communities which the Company owns (including eight communities in which the Company owns varying interests through two separate joint ventures), and 13 communities that the Company manages on behalf of a third-party.
For more information, visit www.sonidaseniorliving.com or connect with the Company on Facebook, X or LinkedIn.
Last Trade: | US$26.05 |
Daily Change: | -0.11 -0.42 |
Daily Volume: | 21,253 |
Market Cap: | US$490.260M |
August 11, 2025 August 15, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load